Statistics

Total Visits

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens13

Select a period of time:

Number of views in the range

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens5

Views

Views
April 20240
May 20240
June 20243
July 20241
August 20240
September 20241
October 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
 

Top cities views

Views
Fort Worth1